CHILDHOOD MASTOCYTOSIS NEW DEVELOPMENTS IN DIAGNOSIS AND TREATMENT

CHI775LDHOOD_MASTOCYTOSI775S_NEW_DEVELOPMENTS_IN_DI775AGNOSI775S_AND_TREATMENTKAPAK

MULTIDISCIPLINARY APPROACH IN THE MANAGEMENT OF CHILDHOOD MASTOCYTOSIS

Ece Tüsüz Önata

Sakarya University, Faculty of Medicine, Sakarya Research and Training Hospital, Department of Pediatric Immunology and Allergy, Sakarya, Türkiye

Tüsüz Önata E. Multidisciplinary Approach in the Management of Childhood Mastocytosis. In: Özdemir Ö, editor. Childhood Mastocytosis: New Developments in Diagnosis and Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.209-217.

ABSTRACT

Mastocytosis is a group of disorders characterized by increased accumulation of mast cells in one or more organs such as skin, bone marrow, liver, spleen and lymph nodes. The majority of pediatric patients have cutaneous mastocytosis with skin involvement only. Since the first presentation of pa- tients with cutaneous mastocytosis (CM) will be to the family physician and general pediatrician, it is important that clinicians are aware and knowledgeable about this disease. Long-term follow-up and treatment of patients is primarily performed by pediatric allergists. However, in some obscure or refrac- tory cases, the involvement of multiple specialties such as pediatric allergist, dermatologist, pathologist or pediatric hematologist in patient management may be required. In this chapter, pediatric CM will be discussed in general terms and the importance and necessity of a multidisciplinary approach in the diagnosis, treatment and long-term follow-up of the disease will be discussed.

Keywords: Childhood mastocytosis; Cutaneous mastocytosis; Mastocytosis management; Multidisciplinary approach

Referanslar

  1. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37(6):435-53. [Crossref]  [PubMed]
  2. Valent P, Sotlar K, Horny HP, Arock M, Akin C. World Health Organization Classification and Diagnosis of Mastocytosis: Update 2023 and Future Perspectives. Immunol Allergy Clin North Am. 2023;43(4):627-649. [Crossref]  [PubMed]
  3. Frieri M, Quershi M. Pediatric Mastocytosis: A Review of the Literature. Pediatr Allergy Immunol Pulmonol.2013;1;26(4):175-180. [Crossref]  [PubMed]  [PMC]
  4. Méni C, Bruneau J, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Damaj G, Hadj-Rabia S et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol.2015;172(3):642-51. [Crossref]  [PubMed]
  5. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016 ;137(1):35-45. [Crossref]  [PubMed]
  6. Lange M, Hartmann K, Carter MC, Siebenhaar F, Alvarez-Twose I, Torrado I et.al. Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. Int J Mol Sci. 2021;4;22(5):2586. [Crossref]  [PubMed]  [PMC]
  7. Polivka L, Rossignol J, Neuraz A, Condé D, Agopian J, Méni C et al. Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up. J Allergy Clin Immunol Pract.2021;9(4):1695-1704.e5. [Crossref]  [PubMed]
  8. Matito A, Azaña JM, Torrelo A, Alvarez-Twose I. Cutaneous Mastocytosis in Adults and Children: New Classification and Prognostic Factors. Immunol Allergy Clin North Am.2018;38(3):351-363. [Crossref]  [PubMed]
  9. Wiechers T, Rabenhorst A, Schick T, Preussner LM, Förster A, Valent P et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136(6):1581-1590.e3. [Crossref]  [PubMed]
  10. Leung AKC, Lam JM, Leong KF. Childhood Solitary Cutaneous Mastocytoma: Clinical Manifestations, Diagnosis, Evaluation, and Management. Curr Pediatr Rev. 2019;15(1):42-46. [Crossref]  [PubMed]  [PMC]
  11. Murphy M, Walsh D, Drumm B, Watson R. Bullous mastocytosis: a fatal outcome. Pediatr Dermatol. 1999 ;16(6):452-5. [Crossref]  [PubMed]
  12. Heide R, Zuidema E, Beishuizen A, Den Hollander JC, Van Gysel D, Seyger MM et al. Clinical aspects of diffuse cutaneous mastocytosis in children: two variants. Dermatology.2009;219(4):309-15. [Crossref]  [PubMed]
  13. Lange M, Niedoszytko M, Nedoszytko B, Łata J, Trzeciak M, Biernat W. Diffuse cutaneous mastocytosis: analysis of
  14. cases and a brief review of the literature. J Eur Acad Dermatol Venereol. 2012;26(12):1565-71. [Crossref]  [PubMed]
  15. Cardoso JM, Cabral CAS, Lellis RF, Ravelli FN. Bullous congenital diffuse cutaneous mastocytosis. An Bras Dermatol.2020;95(2):255-256. [Crossref]  [PubMed]  [PMC]
  16. Sandru F, Petca RC, Costescu M, Dumitrașcu MC, Popa A, Petca A et al. Cutaneous Mastocytosis in Childhood-Update from the Literature. J Clin Med. 2021; 2;10(7):1474. [Crossref]  [PubMed]  [PMC]
  17. Brazel M, Desai A, Are A, Motaparthi K. Staphylococcal Scalded Skin Syndrome and Bullous Impetigo. Medicina (Kaunas).2021;24;57(11):1157. [Crossref]  [PubMed]  [PMC]
  18. Golitz LE, Weston WL, Lane AT. Bullous mastocytosis: diffuse cutaneous mastocytosis with extensive blisters mimicking scalded skin syndrome or erythema multiforme. Pediatr Dermatol.1984;1(4):288-94. [Crossref]  [PubMed]
  19. Oranje AP, Soekanto W, Sukardi A, Vuzevski VD, van der Willigen A, Afiani HM. Diffuse cutaneous mastocytosis mimicking staphylococcal scalded-skin syndrome: reportof three cases. Pediatr Dermatol. 1991;8(2):147-51. [Crossref]  [PubMed]
  20. Nair B, Sonthalia S, Aggarwal I. Solitary mastocytoma with positive Darier's sign. Indian Dermatol OnlineJ.2016;7(2):141-2. [Crossref]  [PubMed]  [PMC]
  21. Gebhard J, Horny HP, Kristensen T, Broesby-Olsen S, Zink A, Biedermann T et al. Validation of dermatopathological criteria to diagnose cutaneous lesions of mastocytosis: importance of KIT D816V mutation analysis. J Eur Acad Dermatol Venereol. 2022;36(8):1367-1375. [Crossref]  [PubMed]
  22. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS. Et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-15. [Crossref]  [PubMed]
  23. Arase N, Wataya-Kaneda M, Murota H, Nakagawa Y, Yamaoka T, Itoi-Ochi S et al. Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients. J Dermatol. 2020;47(4):426-429. [Crossref]  [PubMed]
  24. Morren MA, Hoppé A, Renard M, Debiec Rychter M, Uyttebroeck A, Dubreuil P et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr.2013;162(1):205-7. [Crossref]  [PubMed]
  25. Hoffmann KM, Moser A, Lohse P, Winkler A, Binder B, Sovinz P. et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;1;112(5):1655-7. [Crossref]  [PubMed]
  26. Swarnkar B, Sarkar R. Childhood Cutaneous Mastocytosis: Revisited. Indian J Dermatol. 2023 ;68(1):121. [Crossref]  [PubMed]  [PMC]
  27. Nemat K, Abraham S. Cutaneous mastocytosis in childhood. Allergol Select. 2022;5;6:1-10. [Crossref]  [PubMed]  [PMC]
  28. Brockow K, Ring J, Alvarez-Twose I, Orfao A, Escribano L. Extensive blistering is a predictor for severe complications in children with mastocytosis. Allergy. 2012;67(10):1323-4. [Crossref]  [PubMed]
  29. Alvarez-Twose I, Vañó-Galván S, Sánchez-Muñoz L, Morgado JM, Matito A, Torrelo A et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67(6):813-21. [Crossref]  [PubMed]  [PMC]
  30. Parente R, Pucino V, Magliacane D, Petraroli A, Loffredo S, Marone G et al. Evaluation of vaccination safety in children with mastocytosis. Pediatr Allergy Immunol. 2017;28(1):93-95. [Crossref]  [PubMed]
  31. Bankova LG, Walter JE, Iyengar SR, Lorenzo ME, Hornick JL, Castells MC. Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous mastocytosis. J Allergy Clin Immunol Pract. 2013;1(1):94-6. [Crossref]  [PubMed]
  32. Durmaz A, Özdemir Ö. Clinical spectrum of patients diagnosed with childhood mastocytosis: a retrospective single center experience. European annals of allergy and clinical immunology. 2024. [Crossref]  [PubMed]
  33. Carter MC, Uzzaman A, Scott LM, Metcalfe DD, Quezado Z. Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg. 2008 ;107(2):422-7. [Crossref]  [PubMed]  [PMC]
  34. Ahmad N, Evans P, Lloyd-Thomas AR. Anesthesia in children with mastocytosis--a case based review. Paediatr Anaesth.2009;19(2):97-107. [Crossref]  [PubMed]
  35. Bonadonna P, Lombardo C. Drug allergy in mastocytosis. Immunol Allergy Clin North Am. 2014;34(2):397-405. [Crossref]  [PubMed]
  36. Lange M, Niedoszytko M, Renke J, Gleń J, Nedoszytko B. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27(1):97-102. [Crossref]  [PubMed]
  37. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011;1;12(4):259-70. [Crossref]  [PubMed]  [PMC]
  38. Lange M, Ługowska-Umer H, Niedoszytko M, Wasąg B, Limon J, Żawrocki A et al. Diagnosis of Mastocytosis in Children and Adults in Daily Clinical Practice. Acta Derm Venereol.2016;96(3):292-7. [Crossref]  [PubMed]
  39. Brockow K, Plata-Nazar K, Lange M, Nedoszytko B, Niedoszytko M, Valent P. Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis. Int J MolSci.2021;7;22(5):2684. [Crossref]  [PubMed]  [PMC]
  40. Czarny J, Lange M, Ługowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol Alergol. 2018;35(6):541-545. [Crossref]  [PubMed]  [PMC]
  41. Matito A, Carter M. Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis? Curr Allergy AsthmaRep.2015;15(5):22. [Crossref]  [PubMed]
  42. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63(2):226-32. [Crossref]  [PubMed]
  43. Carter MC, Metcalfe DD, Matito A, Escribano L, Butterfield JH, Schwartz LB et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol.2019;143(3):880-893. [Crossref]  [PubMed]
  44. Jarkvist J, Brockow K, Gülen T. Low Frequency of IgE-Mediated Food Hypersensitivity in Mastocytosis. J Allergy Clin ImmunolPract.2020;8(9):3093-3101. [Crossref]  [PubMed]
  45. Klaiber N, Kumar S, Irani AM. Mastocytosis in Children. Curr Allergy Asthma Rep. 2017;7;17(11):80. [Crossref]  [PubMed]
  46. Siebenhaar F, Weller K, Blume-Peytavi U, Maurer M. Mastozytosen im Kindesalter [Childhood-onset mastocytosis]. Hautarzt.2012;63(2):104-9.German. [Crossref]  [PubMed]
  47. Carter MC, Clayton ST, Komarow HD, Brittain EH, Scott LM, Cantave D. et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136(6):1673-1679.e3. [Crossref]  [PubMed]  [PMC]
  48. Lange M, Nedoszytko B, Górska A, Zawrocki A, Sobjanek M, Kozlowski D. Mastocytosis in children and adults: clinical disease heterogeneity. Arch Med Sci. 2012;4;8(3):533-41. [Crossref]  [PubMed]
  49. Hermans MAW, Arends NJT, Gerth van Wijk R, van Hagen PM, Kluin-Nelemans HC, Oude Elberink HNG et al. Management around invasive procedures in mastocytosis: An update. Ann Allergy Asthma Immunol. 2017;119(4):304-309. [Crossref]  [PubMed]
  50. James PD, Krafchik BR, Johnston AE. Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth.1987;34(5):522-4. [Crossref]  [PubMed]
  51. Matito A, Morgado JM, Sánchez-López P, Álvarez-Twose I, Sánchez-Muñoz L, Orfao A et al. Management of Anesthesia in Adult and Pediatric Mastocytosis: A Study of the Spanish Network on Mastocytosis (REMA) Based on 726 Anesthetic Procedures. Int Arch Allergy Immunol.2015;167(1):47-56. [Crossref]  [PubMed]
  52. González de Olano D, de la Hoz Caballer B, Núñez López R, Sánchez Muñoz L, Cuevas Agustín M, Diéguez MC et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy.2007;37(10):1547-55. [Crossref]  [PubMed]
  53. Özdemir Ö. Management of cutaneous mastocytosis during childhood: Update from the literature. Hitit Medical Journal. 2024;6(1):85-91. [Crossref]
  54. Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JN, Kluin-Nelemans JC, Dubois AE. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med. 2005;63(7):244-9. [PubMed]
  55. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185-96. [Crossref]  [PubMed]
  56. Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol.2012;29(2):222-3. [Crossref]  [PubMed]
  57. Mashiah J, Harel A, Bodemer C, Hadj-Rabia S, Goldberg I, Sprecher E et al. Topical pimecrolimus for paediatric cutaneous mastocytosis. Clin Exp Dermatol. 2018;43(5):559-565. [Crossref]  [PubMed]
  58. Jenkinson HA, Lundgren AD, Carter MC, Diaz LZ, Levy ML. Management of a neonate with diffuse cutaneous mastocytosis: Case report and literature review. Pediatr Dermatol.2019;36(4):486-489. [Crossref]  [PubMed]
  59. Stege H, Schöpf E, Ruzicka T, Krutmann J. High-dose UVA1 for urticaria pigmentosa. Lancet. 1996;347(8993):64. [Crossref]  [PubMed]
  60. Husain Z, Waterman D, Ellison K, DeSimone JA. Management of poorly controlled indolent systemic mastocytosis using narrowband UVB phototherapy. Cutis. 2017;99(5):E30-E33. [PubMed]
  61. Brazzelli V, Grassi S, Merante S, Grasso V, Ciccocioppo R, Bossi G et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32(5-6):238-246. [Crossref]  [PubMed]
  62. Kinsler VA, Hawk JL, Atherton DJ. Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature. Br J Dermatol.2005;152(1):179-80. [Crossref]  [PubMed]
  63. Jendoubi F, Severino-Freire M, Negretto M, Arbus C, Paul C, Bulai Livideanu C. Neuropsychiatric, cognitive and sexual impairment in mastocytosis patients. Orphanet J RareDis.2021;5;16(1):118. [Crossref]  [PubMed]  [PMC]
  64. Spolak-Bobryk N, Niedoszytko M, Jassem E, Chełmińska M, Lange M, Majkowicz M et al. Assessing quality of life in patients with mastocytosis: development of the disease-specific questionnaire. Postepy Dermatol Alergol.2021;38(6):1044-1051. [Crossref]  [PubMed]  [PMC]